Eli Lilly and Company $LLY Stock Sold by Legacy Financial Independent Advisors LLC

Legacy Financial Independent Advisors LLC reduced its holdings in Eli Lilly and Company (NYSE:LLY) by 17.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,672 shares of the company’s stock after selling 579 shares during the quarter. Eli Lilly and Company accounts for 1.5% of Legacy Financial Independent Advisors LLC’s holdings, making the stock its 24th biggest position. Legacy Financial Independent Advisors LLC’s holdings in Eli Lilly and Company were worth $3,092,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the business. Marshall & Sterling Wealth Advisors Inc. grew its position in Eli Lilly and Company by 60.0% in the first quarter. Marshall & Sterling Wealth Advisors Inc. now owns 40 shares of the company’s stock worth $37,000 after buying an additional 15 shares during the last quarter. Torren Management LLC increased its holdings in shares of Eli Lilly and Company by 357.1% in the third quarter. Torren Management LLC now owns 32 shares of the company’s stock valued at $37,000 after buying an additional 25 shares in the last quarter. AlphaCentric Advisors LLC acquired a new stake in shares of Eli Lilly and Company during the 1st quarter valued at $42,000. Foresight Capital Management Advisors Inc. acquired a new stake in shares of Eli Lilly and Company during the 3rd quarter valued at $49,000. Finally, Caitlin John LLC acquired a new stake in shares of Eli Lilly and Company during the 2nd quarter valued at $64,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, CAO Donald Zakrowski sold 2,000 shares of the firm’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the completion of the sale, the chief accounting officer owned 1,526 shares of the company’s stock, valued at $1,808,325.26. This trade represents a 56.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $1,402.52, for a total value of $7,012,600.00. Following the transaction, the executive vice president owned 4,137 shares in the company, valued at $5,802,225.24. This represents a 54.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 13,500 shares of company stock worth $17,020,770 over the last quarter. Corporate insiders own 0.14% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on LLY. Scotiabank raised their price objective on Eli Lilly and Company from $1,300.00 to $1,605.00 and gave the stock a “sector outperform” rating in a research note on Friday, October 30th. Wells Fargo & Company boosted their target price on Eli Lilly and Company from $1,330.00 to $1,500.00 and gave the stock an “overweight” rating in a research report on Friday, October 30th. UBS Group upped their target price on Eli Lilly and Company from $1,425.00 to $1,625.00 and gave the company a “buy” rating in a report on Friday, October 30th. Morgan Stanley upped their target price on Eli Lilly and Company from $1,430.00 to $1,596.00 and gave the company an “overweight” rating in a report on Friday, October 30th. Finally, JPMorgan Chase & Co. increased their price target on Eli Lilly and Company from $1,500.00 to $1,650.00 and gave the company an “overweight” rating in a research report on Friday, October 30th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $1,404.14.

Eli Lilly and Company Trading Up 0.5%

Shares of LLY stock traded up $7.42 during trading hours on Friday, reaching $1,372.15. 3,802,992 shares of the stock traded hands, compared to its average volume of 2,624,130. Eli Lilly and Company has a 1-year low of $850.51 and a 1-year high of $1,453.00. The business has a fifty day moving average price of $1,215.24 and a 200 day moving average price of $1,101.16. The company has a quick ratio of 1.00, a current ratio of 1.39 and a debt-to-equity ratio of 1.17. The firm has a market capitalization of $1.29 trillion, a PE ratio of 44.54, a PEG ratio of 1.77 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, October 29th. The company reported $7.48 EPS for the quarter, topping analysts’ consensus estimates of $5.71 by $1.77. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The firm had revenue of $24.40 billion during the quarter, compared to analyst estimates of $22.58 billion. During the same quarter last year, the business posted $7.02 EPS. The company’s revenue was up 38.6% on a year-over-year basis. On average, equities research analysts forecast that Eli Lilly and Company will post 35.70 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be issued a $1.73 dividend. The ex-dividend date is Friday, November 13th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.5%. Eli Lilly and Company’s dividend payout ratio is presently 22.46%.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly and Hims & Hers agreed to offer FDA-approved Zepbound and Foundayo through Hims & Hers’ telehealth platform. Eligible patients with a prescription can access Lilly’s self-pay prices—reportedly starting at $149—without leaving the platform. The deal could widen patient access and Lilly’s reach in the competitive obesity-treatment market. Lilly and Hims & Hers expand access to FDA-approved Lilly medicines
• Positive Sentiment: New Phase 3 results for investigational retatrutide showed substantial reductions in weight and knee pain among adults with obesity and knee osteoarthritis. Lilly also reported positive Phase 3b results for combining Taltz and Zepbound in people with psoriatic arthritis and obesity, supporting the potential of its medicines in additional patient groups. Lilly to showcase new retatrutide, Taltz and Zepbound data
• Negative Sentiment: Price competition across the GLP-1 market remains a risk to Lilly’s growth and drug margins, as branded treatments compete with lower-priced options and providers seek self-pay patients. Eli Lilly’s GLP-1 franchise faces growing price competition

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management.

The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.

Founded in Indianapolis in 1876 by Colonel Eli Lilly, the company is headquartered in the city and serves patients in markets around the world.